Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Roche to acquire BioVeris

BioVeris Corporation has announced that the Company has reached a definitive agreement under which Roche will acquire BioVeris for $21.50 per share in cash, or a total of approximately $600 million.

From Roche Sequencing and Life Science 5 Apr 2007

Method for making new molecules based on flavonoids - implications for cancer therapeutics

You've heard of them -- the good-for-your-health compounds found in plants that we enjoy in red wine, dark chocolate, green tea and citrus fruits.

5 Apr 2007

Eli Lilly acquires Hypnion

Eli Lilly and Company has announced that it has completed its acquisition of Hypnion, Inc., a privately held neuroscience drug discovery company focused on sleep disorder research.

3 Apr 2007

First time observing real-time molecular interplay within ribosome

The ribosome is a kind of factory for protein in the cell, and as such has long been a prime target for drug discovery. Now, a technological advance by a team at Weill Cornell Medical College is poised to revolutionize research in the field.

21 Mar 2007

ARIUS Research granted two new U.S. patents for antibodies

ARIUS Research has announced that it has been granted two new United States patents for antibodies within their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS' partnered program for melanoma, breast and prostate cancers and protects the valuable site on the disease target that the drug candidate binds to.

8 Mar 2007

Lilly to acquire neuroscience drug discovery co. Hypnion

Eli Lilly and Company and Hypnion, Inc. today announced that they have signed a definitive merger agreement whereby Lilly will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders.

5 Mar 2007

Fox Chase Cancer Center and Cancer Research Technology initiate drug discovery collaboration

Cancer Research Technology Inc. (CRT Inc.) and Fox Chase Cancer Center have announce the initiation of an oncology-focused drug discovery collaboration.

1 Mar 2007

PPD licenses dyslipidemia statin from Ranbaxy

Ranbaxy Laboratories and PPD, Inc. have announced that PPD has acquired an exclusive worldwide license to develop, manufacture and market Ranbaxy's novel statin for the treatment of dyslipidemia.

27 Feb 2007

New patented technology for next generation of DNA and RNA microarrays

A novel invention developed by a scientist from New York Institute of Technology (NYIT) could revolutionize biological and clinical research and may lead to treatments for cancer, AIDS, Alzheimer's, diabetes, and genetic and infectious diseases.

13 Feb 2007

New technologies boost production of malaria drug artemisinin

New technologies that make the large-scale extraction of a natural antimalarial ‘wonder drug' both cheaper and greener are to be developed and trialled in a new European effort.

12 Feb 2007

Natural molecules to create pseudo-cell factories

Carnegie Mellon University's Philip LeDuc predicts the use of artificially created cells could be a potential new therapeutic approach for treating diseases in an ever-changing world.

7 Feb 2007

Ranbaxy and GlaxoSmithKline form alliance

Ranbaxy Laboratories announced today that the Company and GlaxoSmithKline have signed a new, multiyear R&D agreement that modifies and expands the terms of their strategic alliance established in 2003 to provide Ranbaxy expanded drug-development responsibilities and further financial opportunities.

6 Feb 2007

4SC granted U.S. patent for drug to treat rheumatoid arthritis

Martinsried-based drug discovery and development company 4SC AG announced today that the US Patent and Trademark Office (ASPTO) has granted the patent with the US patent number 7,176,241 for its drug candidate SC12267.

6 Feb 2007

Apolipoprotein E gene raises newborns' cerebral palsy risk

Apolipoprotein E (APOE), a gene associated with heightened risk for Alzheimer's disease in adults, can also increase the likelihood that brain-injured newborns will develop cerebral palsy, researchers at Children's Memorial Research Center have discovered.

5 Feb 2007

FoxOs shown to be potential new targets for cancer drugs

In an elegant, multiple-gene knockout experiment, a team of Boston scientists has discovered that a trio of molecules, called FoxOs, are fundamentally critical in preventing some cancers, maintaining blood vessel stability, and in keeping blood-forming stem cells healthy.

29 Jan 2007

Emory University announces new health institute

Emory University announced today a new Global Health Institute that will help address the most pressing health challenges around the world, particularly in poorer nations.

10 Jan 2007

BIO urges Congress to pass Stem Cell Research Enhancement Act

Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), has issued the following statement on H.R. 3, the Stem Cell Research Enhancement Act of 2007.

9 Jan 2007

Amphora sells oncology target to Genentech

Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.

9 Jan 2007

Cytogen issued new patent covering oral drug delivery agents

Cytogen Corporation has announced that it has been issued United States patent number 7,135,457 covering its oral drug delivery agents - random peptide compositions that bind to gastro-intestinal tract (GIT) transport receptors.

28 Nov 2006